{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-021239","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.225268+00:00","generated_at":"2026-06-28T14:02:51.659310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia Q3 revenue $14.7M (+122% QoQ); net loss $50.3M; LUPKYNIS PSF conversion >68%","bullets":["Net revenue $14.7M vs $29K in Q3 2020; net loss $50.3M ($0.39 per share) vs $42.1M loss a year ago.","Cash and investments $286.4M; 2021 revenue guidance maintained at $40-50M.","LUPKYNIS PSFs totaled 412 in Q3; cumulative >1,265; conversion rate improved to >68% from 50% in Q2.","Payer coverage confirmed for 87% of total lives; two preclinical assets AUR200 and AUR300 added.","AURORA 2 final results expected by end of 2021; Swiss MAA filed; EMA decision anticipated Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-021239","json":"https://secwatch.observer/filing/0001628280-21-021239.json","markdown":"https://secwatch.observer/filing/0001628280-21-021239.md","text":"https://secwatch.observer/filing/0001628280-21-021239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021021239/0001628280-21-021239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828021021239/auph-20211103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T14:02:51.659310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}